ChromaDex

ChromaDex

Wellness and Fitness Services

Los Angeles, California 9,227 followers

ChromaDex (NASDAQ: $CDXC) is the global authority on NAD+, focusing on the science of healthy aging.

About us

ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, NIAGEN® (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available. NIAGEN NR is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States*. Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com). ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, to which ChromaDex regularly publishes copies of its press releases, news, and financial information. *Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

Industry
Wellness and Fitness Services
Company size
51-200 employees
Headquarters
Los Angeles, California
Type
Public Company
Founded
1999
Specialties
Ingredient technologies, Reference Standards, Product regulatory and safety consulting, and Consumer Products

Locations

Employees at ChromaDex

Updates

Affiliated pages

Similar pages

Browse jobs

Funding

ChromaDex 13 total rounds

Last Round

Post IPO equity

US$ 3.1M

See more info on crunchbase